To estimate the changes in ovarian reserve following chemotherapy for treatment of cancer with or without GnRHa by determination of the anti-Müllerian hormone (AMH) at 12 months after end of gonadotoxic treatment (EoT) in women with breast cancer. The gene discussed is AMH; the disease is breast cancer.